Amgen Signs US$2 B Licensing Agreement with Synaffix for Next-Generation ADCs

By Lalit Mishra & Lucy Haggerty

Pharma Deals Review: Vol 2023 Issue 2 (Table of Contents)

Published: 3 Feb-2023

DOI: 10.3833/pdr.v2023.i2.2762     ISSN: 1756-7874

Section: Licensing



Demonstrating its continued interest in antibody-drug conjugate (ADC) therapeutics, Amgen has agreed to pay up to US$2 B for exclusive access to Synaffix's ADC technology...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details